Design Therapeutics, Inc.

    Jurisdiction
    United States
    ISIN
    US25056L1035 (DSGN)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    5 / 7

    Profile

    Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€63.91M
    EBIT margin
    0.0%
    Net income
    -€54.15M
    Net margin
    0.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    William Arsani N/A -563K $5.25 -$2.95M

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 265K $1.02M +12K Buy

    Earnings Calls

    Latest earnings call: March 19, 2024 (Q4 2023)

    Add to watchlist

    Notifications